Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)
A biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases with operations in the United States and Europe.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
short term upside very unlikely
Recs
I find it difficult to value hepatitis C stocks but Idenix has risen sharply over the last three weeks without a clear precipitant that I can identify. The company announced plans for a phase II trial of all-oral combination of IDX719 and Janssen's simeprevir in their last earnings call, but this was fairly predictable after the announcement of the Janssen collaboration in January. Hepatitis C may still be an exciting and lucrative field but there's loads of competition and Idenix seems to be years behind in the development of all oral regimens.
Recs
Recs
Over valued.
Recs
went up 269% for portofeille.
Recs
undervalued bio tech
Recs
Despite strong growth in recent months, Gilead Sciences beat them to the punch on hepatitis C, upon which Idenix had hung its hopes. A rebound may take a while.
Recs
It is going to get bought out, likely for more than the 2.5 billion or whatever INHX got. I'm thinking 30-35 bucks per share.
Recs
Wild card is IDIX over ACHN as only remaining Nuc therapy for hep C, as VRUS and INHS both were acquired at huge premium in this narrowed space competing to develop an all-oral hepatitis C therapy for this epidemic worldwide valued at as much as $3 billion. IDIX has broken out but expect it to run up significantly in the near term based on valuation, pipeline, short covers and new valuation of 18.
Recs
There are currently 4000 IDIX shares in my "fund" with break-even of around 5.92 USD.
http://caps.fool.com/Blogs/fund-trades/671856.
Recs
Recs
When should I buy this stock? Plz help....
Recs
spec
Recs
IDIX has a too high valuation compared to its sales potential. It is also loss making.
Recs
Biotech = hot.
Recs
Oversold (but then again, what isn't?!)
Recs
CSOakes @2.51
Recs
Oversold with powerful sponsor. Will rebound for at least a 50% gain.
Recs
worth a buy for a short term correction below $4 after the crash
Recs
The company is sitting on a good amount of cash and has a major backer in the form of Novartis (NVS -- owns over 50% of IDIX's shares). Idenix currently sells a Hepatitis B drug and has a Hep C drug in Phase II trials. They are also working on an HIV drug that is in the extreme early phases of development. The Hep C drug will be used in combination with other drugs, but experienced a setback last year because of GI problems in some patients.
Honestly, I'm not a big biotech/pharma investor, but I like the idea behind this company's products and the potential for both the current Hep B drug and the possible Hep C drug. I generally avoid this realm because I don't have the background to understand the chemistry behind the drugs, but I figured this was an interesting situation to monitor through CAPS. Right now, the market is valuing this company as if it had very little chance at a future. NVS' support and the Hep B drug currently on market seem to mitigate against this pessimism.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 33 : 1 2 Next »